Skip to main content
. 2013 Nov-Dec;7(11-12):E740–E749. doi: 10.5489/cuaj.1213

Table 1.

Baseline patient characteristics, study design and study endpoints

Hudson et al.13 1990 P’ng et al.15 1993 Witjes et al.16 1993 Rogerson14 1994 Heiner et al.12 2008 Gee et al.11 2008 Boorjian et al.10 2009
Study years included Dec 1981–June 1989 1985–1990 Apr 1987–Dec 1991 Dec 1987–Oct 1991 Dec 1999–July 2004 June 1991–Sep 2003 July 1978–Nov 2006
Study type Institution Retrospective

  • - Washington university

  • -Jewish hospital of St Louis

 Retrospective

  • -Royal Brisbane Hospital

  • -Princess Alexandra Hospital

 Retrospective

  • -Dutch Southeast Cooperative Urological Group

 Retrospective
Heidelberg Repatriation Hospital		 Retrospective

  • -Augusta Veterans Affairs Medical Center

  • -Medical College of Georgia

 Retrospective

  • -University of Wisconsin Hospital and Clinics

 Retrospective

  • -Memorial Sloan Kettering Cancer Center
Province/country Missouri, USA Queensland, Australia Netherlands Victoria, Australia Georgia, USA Wisconsin, USA New York, USA
Total patients 162 45 313 56 58 154 1218
Included patients 149 45 183 38 58 43 907
Inclusion selection criteria Available medication record All patients included N/A Available medication record N/A Available records

  • - Available records,

  • -No prior surgical intervention

  • - >1990
Anticoagulant G1 29 9 42 13 7 20 221
Control G2 120 36 141 25 51 23 686
Male: Female ratio Statistical significance N/A 33:12 N/A N/A N/A 36:7
More males in G1 (NS)		 721:186
More males in G1
(p < 0.01)
Age, years (range) Statistical significance N/A Mean both groups: 69 (36–92) N/A N/A N/A Mean

  • -G1: 72

  • -G2: 63


p < 0.01		 Median

  • -G1: 69

  • -G2: 65


p < 0.01
Follow-up (range) Mean

  • -G1: 26.5 months

  • -G2: 29.8 months

 Mean both groups 20.3 months
Median both groups 16 months (3–56)		 Mean

  • -G1: 22.5 months (4.4–49.5)

  • -G2: 20.8 months (2.6–53.2)

 Mean varied among stages ranging from 6 to 28 months (2-36) N/A N/A Median 4.2 years in patients without recurrence and 3.7 years without progression
Primary endpoint studied Tumour recurrence Persistent or recurrence tumour at first follow-up in 3 months Disease (recurrence) free interval Persistent or recurrence disease at 6 weeks Response to therapy categorized in relation to age

  • - 1: (complete)

  • - 2: (recurrence at increase interval or dec. grade/stage

  • - 3: (recurrence same interval or same stage/grade)

  • - 4: (recurrence shorter interval or higher stage/grade)

 Recurrence-free and progression-free intervals Tumour recurrence and progression to open surgery

G: group; N/A: not available